Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You don’t need to pre-fund. Attorneys take 1/3 of spoils. I was in one on another stock that had a class action, and received a check 18 months later. Company settled and their insurance paid majority of the claim.
They have been doing that for years unfortunately.
Click the link.
Click the likes.
You will see a list of everyone that liked the tweet.
Scroll to you see his name.
Sorry, can’t screen shot via this app.
I hope @drgauravchandra has some sort of plan for all of us that followed HIS lead & comments as to what $ENZC had and why we all invested. Are we going to still be rewarded as promised (many times) or were the bashers actually right? Maybe a “like” tells me we are still good 🙏🏻
— KeyWestPlease (@KeyWestPlease23) April 22, 2024
Chandra liking a tweet today about saving the shareholders. WOW, that takes balls of steel!
lol!
Is this company the only one who has ability to do 1200+ qubits processing speed/power? IONq is soon be at 64 qubits, that’s big difference. Anyone else in the same league as D Wave?
Also, what will happen to Bitcoin when a quantum computer can process 2600 qubits? At 25xx, Bitcoin can be comprised.
Lockheed submitted offer to buy LLAP
Check out this speaker interview with @MedarovaZdravka as we gear up for the RNAi- Based Therapeutics Summit. pic.twitter.com/ker6yb2aXV
— TransCode Therapeutics (@RNAoncology) January 30, 2024
Going private
Wow! What’s the news Taco?
It was never actual money. Its shares given at $360m valuation (36m shares of saga at $10 each)
Where the money going? Saga dividend to shareholders gets lower each announcement, yet the shares enzc is getting remains the same.
WHERE IS THE REST OF THE MONEY GOING?
Only way they cure HIV is if someone injects them with virus. That’s the only sure motivation to do what’s right for the company.
Are you kidding. They lied to investors for 3 years and show a partner of habit.
They did screwed Bioclonetics investors and gave them more shares in ENZC. Now they are reducing your stake in saga (percentage wise) while increasing theirs again!
Add this to the lawsuit claim.
2 years and 5 months with still no evidence.
The results will be made public as we receive them from the University. Novel innovative approach can sometimes take longer than expected. This test result helps us characterize our Anti-HIV-Monoclonal Antibody better and has no bearing on our other scheduled milestones.
— Gaurav Chandra M.D. (@drgauravchandra) June 23, 2021
What shares were issued? There was a proposal of shares part of the binding agreement. However, the deal isn’t closed. Thus, no issued shares to anyone.
Shorts just covered. Short lived success
Plagiarize much?
Lol. Dildos, pills, drugs, short and bull all at the same time
That’s what you said.
Halted?
I wish. Too early on a school night
Anyone know why the news notifications on this stock keep going flashing on and off today?
Agreed. I saw the other this morning and did the math. The shares should be over $6, but the market is clearly flipping and not holding shit. Just as it happened here.
The $80m upfront for 22% equity suggest the market cap should be about $363m + other assets.
Yep. Happens to lots of bios. The bigger the market and science confirmed, the bigger the check will be.
Easily. I’m foreseeing a $150m-$300m upfront payment after Phase 1/2 completed showing proof of concept for about 25-30% equity stake or licensing deal on TTX-MC138 alone.
Close, but not that low. Lol.
I feel comfortable where everything is at currently. Even if they gave up equity for cash/diluted, the upside is ridiculous. Anything under a $100m MC is bonkers. Deal of the decade.
Maybe you. I didn’t buy this at $100, or $1, nor $0.50.
They have announced offerings and cancelled before. I wonder if they are in talks with a partner but they are requiring certain milestones to be hit first. The last filing said they probably would need more cash by September this year. After further review, maybe they are focusing financials on TTX-MC138 get Phase 1 started asap so a partner can help fund it. That’s coming up pretty quick.
Did shorts finally cover? Letting it run a day or two?
An article to go along with the manipulation.
https://www.allpennystocks.com/specialreportsus/3403/biotech-shares-bid-up-following-public-offering-cancellation?utm_source=advfn
Trying to scare people again with a few shares
Tomorrow would be great to announce a partnership with financial backing and milestone payments.
True, but look at the recent PRs going back 5 months. They have laid out the plan. They have hit every milestone when they said they have. I'm guessing there is some news about to pop to put them on the map for a while. However, the market in general is bearish AF right now. Just hope whatever they have up their sleeves is juicy enough to make headlines or it will be short lived.
Doubt it. Per filings they have 290m AS and 20m OS (after reverse split). There is only one reason to do an offering if they wanted to be bought out. That reason is to appear to be in a position of strength to continue business operations as if no buyout were to occur. Their IP is impressive, but doubt a buyout is in the works until P1/2 is completed. It would be amazing if they could find a partner to fund trials/operations for equity in the company. As long as the OS stays under 100m by the time Phase 1/2 is complete, they are in good shape long term. Short term, they have a lot of "ideas" to grow the pipeline which will cost a lot. Ideally, the CEO should do one last offering to get TTX-MC138 past P1/2. License that out with milestone payments to fund the next round in the pipeline. Rinse and repeat until a buyout happens.
Sounds like they are wanting a buyout from the letter to shareholders in August….
“Over the past two years, the biotech sector has faced a substantial downturn that industry experts consider the most significant in the last two decades. Our success in raising capital from institutional investors against this backdrop further encourages us that we are on the right track. Major pharmaceutical companies are compelled to actively seek fresh drug candidates to renew their pipelines ahead of impending patent expirations. Development stage biotech companies, such as TransCode Therapeutics, play a crucial role as the sources from which these large companies discover their next potential candidates.”